$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121723423000096 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$70.30M	$77.26M	$79.42M
YoY Change	-12.81%	-2.71%	17.83%
Cost Of Revenue	$25.89M	$25.97M	$26.88M
YoY Change	-6.0%	-3.41%	24.57%
Gross Profit	$44.41M	$51.30M	$52.53M
YoY Change	-16.35%	-2.36%	14.65%
Gross Profit Margin	63.18%	66.39%	66.15%
Selling, General & Admin	$50.96M	$51.26M	$49.71M
YoY Change	-2.35%	3.13%	62.04%
% of Gross Profit	114.73%	99.94%	94.62%
Research & Development	$20.23M	$24.36M	$21.88M
YoY Change	-10.6%	11.32%	36.72%
% of Gross Profit	45.56%	47.48%	41.65%
Depreciation & Amortization	$3.666M	$3.427M	$2.619M
YoY Change	33.6%	30.85%	34.31%
% of Gross Profit	8.25%	6.68%	4.99%
Operating Expenses	$97.93M	$101.6M	$98.47M
YoY Change	-4.33%	3.17%	44.26%
Operating Profit	-$27.62M	-$24.32M	-$19.05M
YoY Change	27.19%	27.66%	2120.63%
Interest Expense	$2.871M	$2.666M	$189.0K
YoY Change	500.63%	1310.58%	50.0%
% of Operating Profit
Other Income/Expense, Net	$2.603M	$699.0K	-$607.0K
YoY Change	-9740.74%	-215.16%	559.78%
Pretax Income	-$25.02M	-$23.63M	-$19.66M
YoY Change	15.06%	20.17%	1969.47%
Income Tax	-$68.00K	$124.0K	-$12.00K
% Of Pretax Income
Net Earnings	-$24.95M	-$23.75M	-$19.65M
YoY Change	15.01%	20.87%	2759.97%
Net Earnings / Revenue	-35.49%	-30.74%	-24.74%
Basic Earnings Per Share	-$0.46	-$0.44	-$0.37
Diluted Earnings Per Share	-$0.46	-$0.44	-$0.37
COMMON SHARES
Basic Shares Outstanding	53.79M shares	53.67M shares	53.02M shares
Diluted Shares Outstanding	53.85M shares	53.64M shares	53.02M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$286.0M	$288.5M	$321.9M
YoY Change	-7.33%	-10.38%	-13.99%
Cash & Equivalents	$87.79M	$74.66M	$171.9M
Short-Term Investments	$198.2M	$213.9M	$150.1M
Other Short-Term Assets	$7.676M	$8.161M	$8.733M
YoY Change	-11.33%	-6.55%	19.63%
Inventory	$18.84M	$18.02M	$18.21M
Prepaid Expenses
Receivables	$51.63M	$59.31M	$65.32M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$360.8M	$371.4M	$411.5M
YoY Change	-10.66%	-9.74%	-6.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.08M	$35.51M	$27.56M
YoY Change	9.66%	28.81%	141.83%
Goodwill	$39.70M	$39.60M	$37.00M
YoY Change	7.01%	7.03%	41.76%
Intangibles	$43.53M	$45.64M	$48.15M
YoY Change	-6.02%	-5.22%	5.92%
Long-Term Investments
YoY Change
Other Assets	$2.036M	$2.080M	$5.192M
YoY Change	-59.74%	-59.94%	419.2%
Total Long-Term Assets	$154.0M	$156.8M	$135.2M
YoY Change	12.08%	15.95%	31.9%
TOTAL ASSETS
Total Short-Term Assets	$360.8M	$371.4M	$411.5M
Total Long-Term Assets	$154.0M	$156.8M	$135.2M
Total Assets	$514.8M	$528.2M	$546.7M
YoY Change	-4.89%	-3.38%	1.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.880M	$12.86M	$10.61M
YoY Change	-41.51%	21.27%	-8.55%
Accrued Expenses	$39.10M	$34.02M	$33.46M
YoY Change	9.03%	1.68%	64.0%
Deferred Revenue	$6.058M	$5.841M	$3.941M
YoY Change	41.05%	48.21%	11.9%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$74.50M	$71.83M	$66.92M
YoY Change	-5.05%	7.33%	46.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$247.0K	$248.0K	$253.0K
YoY Change	-1.98%	-1.98%	-47.29%
Total Long-Term Liabilities	$247.0K	$248.0K	$253.0K
YoY Change	-1.98%	-1.98%	-47.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.50M	$71.83M	$66.92M
Total Long-Term Liabilities	$247.0K	$248.0K	$253.0K
Total Liabilities	$109.6M	$108.2M	$89.17M
YoY Change	12.14%	21.34%	27.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$509.9M	-$484.9M	-$402.8M
YoY Change	20.12%	20.38%	14.04%
Common Stock	$923.6M	$912.3M	$865.5M
YoY Change	5.52%	5.42%	4.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$405.2M	$420.0M	$457.5M
YoY Change
Total Liabilities & Shareholders Equity	$514.8M	$528.2M	$546.7M
YoY Change	-4.89%	-3.38%	1.01%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$24.95M	-$23.75M	-$19.65M
YoY Change	15.01%	20.87%	2759.97%
Depreciation, Depletion And Amortization	$3.666M	$3.427M	$2.619M
YoY Change	33.6%	30.85%	34.31%
Cash From Operating Activities	-$499.0K	$671.0K	-$21.47M
YoY Change	-87.13%	-103.13%	-36.16%
INVESTING ACTIVITIES
Capital Expenditures	$2.362M	$2.771M	-$8.563M
YoY Change	-135.53%	-132.36%	-785.04%
Acquisitions		$4.562M	$0.00
YoY Change			-100.0%
Other Investing Activities	$17.71M	-$12.00M	-$147.5M
YoY Change	138.1%	-91.86%	-784.95%
Cash From Investing Activities	$15.35M	-$14.77M	-$156.0M
YoY Change	1842.78%	-90.53%	-917.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.566M	-$1.138M	$865.0K
YoY Change	-21.58%	-231.56%	-99.54%
NET CHANGE
Cash From Operating Activities	-499.0K	$671.0K	-$21.47M
Cash From Investing Activities	15.35M	-$14.77M	-$156.0M
Cash From Financing Activities	-1.566M	-$1.138M	$865.0K
Net Change In Cash	13.28M	-$15.26M	-$176.6M
YoY Change	-361.27%	-91.36%	-201.11%
FREE CASH FLOW
Cash From Operating Activities	-$499.0K	$671.0K	-$21.47M
Capital Expenditures	$2.362M	$2.771M	-$8.563M
Free Cash Flow	-$2.861M	-$2.100M	-$12.91M
YoY Change	-203.25%	-83.73%	-63.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q1	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2022#PostemploymentRetirementBenefitsMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36536
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CAREDX, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3316839
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	8000 Marina Boulevard, 4th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Brisbane
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94005
CY2023Q1	dei	City Area Code CityAreaCode	415
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	287-2300
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CDNA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53793067	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74660000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89921000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	211279000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	203168000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59310000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	66312000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	18018000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19232000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8161000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9216000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	371428000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	387849000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	35506000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	35529000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33431000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34689000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45637000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43051000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	39615000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	37523000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	520000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	522000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2080000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3828000	usd
CY2023Q1	us-gaap	Assets Assets	528217000	usd
CY2022Q4	us-gaap	Assets Assets	542991000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12861000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9942000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12082000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16902000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	46885000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	49131000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	71828000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	75975000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	25000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	32000	usd
CY2023Q1	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	4089000	usd
CY2022Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	2418000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32006000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33406000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	248000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	249000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	108196000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	112080000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53712654	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53583301	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53653182	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53533250	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	52000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	52000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	912291000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	898806000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7439000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7503000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-484883000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-460444000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	420021000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	430911000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	528217000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	542991000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77262000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79416000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24357000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21880000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	23231000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	23148000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28032000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26559000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	101586000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	98469000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24324000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19053000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2666000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	189000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	27000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1974000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-823000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	699000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-607000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23625000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19660000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-23749000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19648000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53643216	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53015459	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53643216	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53015459	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-23749000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-19648000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	64000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-420000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23685000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20068000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	430911000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	456000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	690000	usd
CY2023Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-785000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	93000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13719000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	64000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-23749000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	420021000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	465876000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	999000	usd
CY2022Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1482000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2590000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	58000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1598000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10563000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19648000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	457544000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-23749000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-19648000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13754000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10634000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3427000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2619000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1000000	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1337000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	915000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-905000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-507000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	364000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	64000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	773000	usd
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-139000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7664000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5591000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1217000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1060000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1515000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	567000	usd
CY2023Q1	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1333000	usd
CY2022Q1	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-969000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1549000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-4888000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-14634000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2352000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7916000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	217000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	671000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21468000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4562000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	100000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	86310000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	148522000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	78972000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1053000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	100000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2023Q1	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	2771000	usd
CY2022Q1	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	8463000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14771000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-156032000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	456000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	999000	usd
CY2023Q1	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	656000	usd
CY2022Q1	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	1482000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1598000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	250000	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	250000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	690000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1138000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	865000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-25000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15263000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-176590000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90443000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	348696000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75180000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172106000	usd
CY2023Q1	cdna	Unsubmitted Claims Revenue Not Yet Recognized UnsubmittedClaimsRevenueNotYetRecognized	8900000	usd
CY2018Q1	cdna	Number Of Renal Transplant Patients NumberOfRenalTransplantPatients	1700	patient
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-484900000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	285900000	usd
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	50000000	usd
CY2022Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P2Y
CY2023Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	59472	shares
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	700000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	48700000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, approximately 42% and 54%, respectively, of total revenue was derived from Medicare. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, approximately 26% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March 31, 2023 or December 31, 2022.</span></div>
CY2023Q1	cdna	Unsubmitted Reimbursement Claims For Medicare UnsubmittedReimbursementClaimsForMedicare	3200	unique_solution
CY2023Q1	cdna	Unsubmitted Claims Revenue Not Yet Recognized UnsubmittedClaimsRevenueNotYetRecognized	8900000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23749000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23749000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19648000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19648000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53643216	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53643216	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53015459	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53015459	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7347842	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4142211	shares
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3475000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4939000	usd
CY2023Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1000000	usd
CY2023Q1	cdna	Business Combination Contingent Consideration Liability Measurement Input Discount Rate BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate	0.07
CY2022	cdna	Business Combination Contingent Consideration Liability Measurement Input Discount Rate BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate	0.12
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74660000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171892000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	520000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	214000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75180000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172106000	usd
CY2023Q1	cdna	Marketable Securities Amortized Cost Short Term MarketableSecuritiesAmortizedCostShortTerm	211279000	usd
CY2023Q1	cdna	Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm	1335000	usd
CY2023Q1	cdna	Marketable Securities Fair Value Short Term MarketableSecuritiesFairValueShortTerm	212614000	usd
CY2023Q1	cdna	Marketable Securities Amortized Cost Long Term MarketableSecuritiesAmortizedCostLongTerm	5100000	usd
CY2023Q1	cdna	Marketable Securities Accumulated Unrecognized Holding Gain Loss Long Term MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm	-3828000	usd
CY2023Q1	cdna	Marketable Securities Fair Value Long Term MarketableSecuritiesFairValueLongTerm	1272000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	79114000	usd
CY2023Q1	cdna	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	216379000	usd
CY2023Q1	cdna	Marketable Securities Accumulated Unrecognized Gain Loss MarketableSecuritiesAccumulatedUnrecognizedGainLoss	-2493000	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	213886000	usd
CY2022Q4	cdna	Marketable Securities Amortized Cost Short Term MarketableSecuritiesAmortizedCostShortTerm	203168000	usd
CY2022Q4	cdna	Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm	232000	usd
CY2022Q4	cdna	Marketable Securities Fair Value Short Term MarketableSecuritiesFairValueShortTerm	203400000	usd
CY2022Q4	cdna	Marketable Securities Amortized Cost Long Term MarketableSecuritiesAmortizedCostLongTerm	5000000	usd
CY2022Q4	cdna	Marketable Securities Accumulated Unrecognized Holding Gain Loss Long Term MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm	-2924000	usd
CY2022Q4	cdna	Marketable Securities Fair Value Long Term MarketableSecuritiesFairValueLongTerm	2076000	usd
CY2022Q4	cdna	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	208168000	usd
CY2022Q4	cdna	Marketable Securities Accumulated Unrecognized Gain Loss MarketableSecuritiesAccumulatedUnrecognizedGainLoss	-2692000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	205476000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	211279000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	203168000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	211279000	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	203168000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	39600000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	37500000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	77864000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28766000	usd
CY2023Q1	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	4711000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44387000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28766000	usd
CY2023Q1	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	4711000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45637000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73764000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27175000	usd
CY2022Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	4788000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	41801000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	75014000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27175000	usd
CY2022Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	4788000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43051000	usd
CY2021Q4	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	13400000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1590000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1623000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	4861000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6246000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6077000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5136000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5122000	usd
CY2023Q1	cdna	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	16945000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44387000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3247000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2962000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4713000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4306000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10058000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11964000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	18018000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19232000	usd
CY2023Q1	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	13883000	usd
CY2022Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	14816000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8262000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6115000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5738000	usd
CY2023Q1	cdna	Number Of Warrants Exercised NumberOfWarrantsExercised	0	shares
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5591000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5841000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5342000	usd
CY2023Q1	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2641000	usd
CY2022Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2062000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2087000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4633000	usd
CY2023Q1	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	1760000	usd
CY2022Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	2189000	usd
CY2023Q1	cdna	Accrued License And Other Collaboration Fees AccruedLicenseAndOtherCollaborationFees	1017000	usd
CY2022Q4	cdna	Accrued License And Other Collaboration Fees AccruedLicenseAndOtherCollaborationFees	1000000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	825000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1025000	usd
CY2023Q1	cdna	Accrued Shipping Expenses AccruedShippingExpenses	459000	usd
CY2022Q4	cdna	Accrued Shipping Expenses AccruedShippingExpenses	489000	usd
CY2023Q1	cdna	Accrued Capital Expenditures AccruedCapitalExpenditures	0	usd
CY2022Q4	cdna	Accrued Capital Expenditures AccruedCapitalExpenditures	1316000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4372000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4553000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	46885000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	49131000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33400000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5700000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32000000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1983000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1413000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	1983000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	1413000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-500000	usd
CY2022Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	500000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5854000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7931000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7681000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7019000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7166000	usd
CY2023Q1	cdna	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	10604000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46255000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8511000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	37744000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5738000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32006000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1333000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	972000	usd
CY2014Q2	cdna	Number Of Milestone Payments NumberOfMilestonePayments	6	milestone_payment
CY2022Q4	us-gaap	Malpractice Insurance Maximum Coverage Per Incident MalpracticeInsuranceMaximumCoveragePerIncident	15000000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2022Q1	cdna	Number Of Warrants Exercised NumberOfWarrantsExercised	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1490462	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2921925	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.13
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2141330	shares
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices	7649	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1262588	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	418564	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	418564	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.50
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	820	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.06
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	25.39
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans	50254	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	91291	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12949	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12949	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.32
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	78024	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	78024	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	33.81
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2175509	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3248696	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.52
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0.0	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000.0	usd
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	1273	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10634000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P5Y8M19D
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	1558000	usd
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	1695	shares
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	27.05
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y11M19D
CY2023Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	3000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2968	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1561000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13754000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77262000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79416000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35506000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35529000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	60000.00	usd

Files In Submission

Name	View Source	Status
cdna-20230331_def.xml	Edgar Link	unprocessable
cdna-20230331_cal.xml	Edgar Link	unprocessable
0001217234-23-000096-index-headers.html	Edgar Link	pending
0001217234-23-000096-index.html	Edgar Link	pending
0001217234-23-000096.txt	Edgar Link	pending
0001217234-23-000096-xbrl.zip	Edgar Link	pending
cdna-20230331.htm	Edgar Link	pending
cdna-20230331.xsd	Edgar Link	pending
cdna-20230331x10qxexx101.htm	Edgar Link	pending
cdna-20230331x10qxexx311.htm	Edgar Link	pending
cdna-20230331x10qxexx312.htm	Edgar Link	pending
cdna-20230331x10qxexx321.htm	Edgar Link	pending
cdna-20230331x10xqxexx102.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
cdna-20230331_pre.xml	Edgar Link	unprocessable
cdna-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdna-20230331_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2023 Q2 Form 10-Q Financial Statement

#000121723423000096 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2023 Q2 Form 10-Q Financial Statement

#000121723423000096 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna